Invenra is focused on developing the next generation of best-in-class biologics, with an emphasis on multispecific antibodies and their derivatives. Invenra's proprietary technologies combine our highly developable B-Body™ bispecific platform with high throughput functional screening, enabling the optimization of unprecedented numbers of bispecific antibodies in phenotypic assays. Invenra has a pipeline of immuno-oncology bispecific antibodies that are currently in preclinical studies.
Location: United States, Wisconsin, Madison
Employees: 11-50
Founded date: 2011
Investors 2
| Date | Name | Website |
| - | Rose Ventu... | roseventur... |
| - | New Capita... | newcapital... |
Mentions in press and media 2
| Date | Title | Description |
| 27.02.2013 | Quiet Wisconsin startup raises $3 million for drug-discovery platform for biologics | According to its website, Invenra says peptide and protein drugs have the potential to hit many previously “undruggable” drug targets because of their molecular structure and size. Its proprietary technology allows the company’s scientists ... |
| - | Quiet Wisconsin startup raises $3 million for drug-discovery platform for biologics | Biologic drugs are filling the pipelines of big pharmaceutical companies and niche biotech companies, and many expect the market for these drugs to soar. But discovery and development of biologics is complex, time-consuming and expensive be... |